VaDDC
  • About
    • Join VaDDC
    • Affiliated Organizations
  • Leadership
    • Executive committee members
  • Events
    • VaDDRx 2022: Cardiovascular, Pulmonary, and Metabolic Disease
    • VaDDRx: CoronaVirus Therapeutics, Present and Future 2021
    • VaDDRx: Emerging Targets, Technologies and Therapeutics for Cancer and Neuroscience 2019
    • VirginiaDrugDiscoveryRx 2018
    • VirginiaCancerRx 2017
    • VirginiaBrainRx 2016
  • News
  • Partnerships
    • Industry Initiatives
    • Featured Collaborations
    • Become a Sponsor
Select Page
Carlier & Slade receive grant to develop new malaria therapeutics

Carlier & Slade receive grant to develop new malaria therapeutics

by Discovery | Feb 7, 2017 | Uncategorized

A team headed by Paul Carlier, Professor of Chemistry, Virginia Tech has received funding from the National Institutes of Health to carry out lead optimization on antimalarial drug candidate MMV008138. Carlier, who is Deputy Director of the Virginia Tech Center for...

Recent Posts

  • Executive Committee Chair Paul Carlier Chosen as Director of UIChicago’s UICentre
  • Exec. Committee Member Beth Sharlow on UVA’s Fiske Drug Discovery Lab
  • KeViRx Selected as Part of BLUE KNIGHT™ Collaboration for Global Health Preparedness
  • Desai Grant on Factor XIa Inhibitors Funded
  • KeViRx-UVA-ODU Collaborative SBIR Grant funded

Archives

  • July 2022
  • March 2022
  • February 2022
  • January 2022
  • October 2021
  • September 2021
  • August 2021
  • June 2021
  • June 2020
  • May 2020
  • July 2019
  • March 2019
  • December 2018
  • November 2018
  • September 2018
  • September 2017
  • June 2017
  • May 2017
  • February 2017
  • December 2016
  • November 2016
  • September 2016
  • July 2016
  • April 2015
© 2016 Virginia Drug Discovery Consortium | website by michaelclapp.info